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Available online 28 January 2016Dendritic cells (DCs) are major antigen-presenting cells that can efﬁciently prime and cross-prime antigen-
speciﬁc T cells. Delivering antigen to DCs via surface receptors is thus an appealing strategy to evoke cellular
immunity. Nonetheless, whichDC surface receptor to target to yield the optimal CD8+ and CD4+ T cell responses
remains elusive. Herein, we report the superiority of CD40 over 9 different lectins and scavenger receptors at
evoking antigen-speciﬁc CD8+ T cell responses. However, lectins (e.g., LOX-1 and Dectin-1) were more efﬁcient
than CD40 at eliciting CD4+ T cell responses. Common and distinct patterns of subcellular and intracellular local-
ization of receptor-bound αCD40, αLOX-1 and αDectin-1 further support their functional specialization at en-
hancing antigen presentation to either CD8+ or CD4+ T cells. Lastly, we demonstrate that antigen targeting to
CD40 can evoke potent antigen-speciﬁc CD8+ T cell responses in human CD40 transgenic mice. This study pro-
vides fundamental information for the rational design of vaccines against cancers and viral infections.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Dendritic cells (DCs) are professional antigen presenting cells
(APCs) that can efﬁciently prime T cells. Both endogenous and exoge-
nous antigens are efﬁciently presented by DCs in the context of major
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. This is an open access article undercomplexes. Among various types of APCs, DCs are the most efﬁcient at
cross-presenting antigens to T cells (Delamarre and Mellman, 2011;
Jung et al., 2002; Segura and Villadangos, 2009), although the types
andmagnitude of T cell responses largely rely on the functional special-
ty and plasticity of DC subsets.
T cell-mediated immunity plays crucial roles in therapeutic immuni-
ty against cancers and viral infections. The potent ability of DCs to cross-
prime CD8+ T cells positions them as novel cellular targets for the ratio-
nal design of vaccines. In line with this premise, Bonifaz et al. (2002,
2004) demonstrated that the efﬁciency of antigen cross-presentation
by DCs, assessed by measuring the magnitude of antigen-speciﬁc
CD8+ T cell responses, could be improved over 100-fold by targeting
antigens to DEC205 in mice. This seminal observation has led many
scientists to further study the biology of DC surface receptors and the
use of the “DC-targeting vaccines” against cancers and viral infections.
For more than a decade, researchers have been attempting to
optimize DC-targeting vaccines by delivering antigens to different DC
surface receptors. These receptors include c-type lectins (e.g., DEC205,
DC-SIGN, CD207, LOX-1, DC-ASGPR, Dectin-1, DCIR, DCIR2, CLEC6,
CLEC9A, and CLEC12A) (Bonifaz et al., 2004; Caminschi et al., 2008;
Carter et al., 2006; Delneste et al., 2002; Dudziak et al., 2007; Duluc
et al., 2014; Flacher et al., 2014; Flamar et al., 2013; Idoyaga et al.,
2008, 2011; Kastenmuller et al., 2014; Lahoud et al., 2009; Li et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
47W. Yin et al. / EBioMedicine 5 (2016) 46–582012; Meyer-Wentrup et al., 2008; Ni et al., 2010; Sancho et al.,
2008; Tacken et al., 2005, 2007, 2011; Weck et al., 2008), as well as
non-lectin receptors, including CD40 (Chatterjee et al., 2012; Cohn
et al., 2013; Flamar et al., 2013; Rosalia et al., 2015; Williams et al.,
2012), mannose receptor (Tsuji et al., 2011), and integrins (Castro
et al., 2008). Antigens delivered to DCs via each of these receptors
have been reported to elicit certain levels of antigen-speciﬁc CD8+ T
cell responses in vitro in humans and in vivo in mice or non-human pri-
mates (NHPs). However, it still remains unclear which targeted recep-
tors are the most efﬁcient at priming and boosting antigen-speciﬁc
CD8+ and CD4+ T cell responses. Finding a speciﬁc DC surface receptor
that permits us to efﬁciently evoke potent CD8+ and CD4+ T cell re-
sponses will be fundamental for the rational design of effective DC-
targeting vaccines against cancers and viral infections. Recent pre-
clinical (in NHPs) and clinical data of DEC205-targeting vaccines
also suggest that efﬁcient priming and activation of antigen-
speciﬁc CD8+ cytotoxic T lymphocytes (CTLs) are still major challenges
for the success of DC-targeting vaccines for cancer immunotherapy
(Kastenmuller et al., 2014). However, it is also important to note that
CD4+ T cells are crucial for the longevity of memory CD8+ CTL-
mediated immunity (Janssen et al., 2003), which will determine the ef-
ﬁcacy of vaccines in many circumstances.
In this study, we ﬁrst compared nine different human DC surface
receptors for their ability to promote antigen cross-presentation to
CD8+ T cells. We found that CD40 was the most efﬁcient at priming
and boosting antigen-speciﬁc CD8+ CTLs that were functional.
We then compared CD40 with the two best DC lectins, LOX-1 and
Dectin-1, for their ability to present antigens to CD4+ T cells.
Interestingly, both LOX-1 and Dectin-1 were superior to CD40 at
evoking antigen-speciﬁc CD4+ T cell responses. To assess themechanis-
tic insights of the functional dichotomy of CD40 versus lectins
(e.g., LOX-1 and Dectin-1) in antigen presentation to CD8+ and CD4+
T cells, we have examined subcellular and intracellular trafﬁcking
of the three different receptor-bound antibodies in DCs. We further
investigated the kinetics of antigen cross-presentation by DCs targeted
with antigen via different receptors. Lastly, we were able to show that
antigen targeting to CD40 results in potent CD8+ T cell responses in
vivo using human CD40 transgenic (hCD40Tg) mice. This in vivo
model further allowed us to conclude that CD40 is superior to Langerin,
another lectin receptor, at evoking antigen-speciﬁc CD8+ T cell
responses, while targeting antigen to Langerin resulted in greater levels
of antigen-speciﬁc CD4+ T cell responses than targeting to CD40.2. Materials and Methods
2.1. Antibodies, Peptides, Tetramers and Other Reagents
Monoclonal antibodies (mAbs) speciﬁc to CD4, CD8, CD11c, CD80,
CD83, CD86, perforin and interferon (IFN)γ were purchased from
BioLegend. mAbs speciﬁc to CD3, CD19, CD123, Lin-1, HLA-DR,
CD45RA, and CD45RO were purchased from BD Biosciences. mAbs to
CD14 and HLA-ABC were purchased from eBioscience. LIVE/DEAD
ﬁxable dead cell stain kit and mAbs to granzyme B were from
Invitrogen. HLA-A*0201-inﬂuenza virus matrix protein 1 (Flu.M1) 58–66,
HLA-A*0201-melanoma antigen recognized by T cells 1 (MART-1) 26–35,
and H-2Db-human papillomavirus (HPV) 16.E749–57 tetramers were
from Beckman Coulter. Flu.M158–66 and MART-126–35 (27L) peptides
were synthesized by Bio-Synthesis. Overlapping 15-mer peptides
(staggered by 11 amino acids) spanning the entire nucleoprotein (NP)
(A/environment/Viet Nam/1203/2004 H5N1) and hemagglutinin
subunit 1 (HA1) (A/PR/8/34 H1N1), HPV16.E6 and E7 proteins
and human prostate speciﬁc antigen (PSA) were purchased from
Mimotopes. Carboxyﬂuorescein succinimidyl ester (CFSE) (Invitrogen)
was used for measuring CD8+ T cell proliferation. Human granulocyte-
macrophage colony-stimulating factor (GM-CSF) was purchasedfrom the Baylor University Medical Center Investigational Pharmacy.
Interleukin (IL)-2, IL-4, IL-7, and IL-15 were purchased from PeproTech.
2.2. DC-targeting mAbs
mAbs speciﬁc for the ectodomains of human receptors [αLOX-1
(15C4) (Li et al., 2012), αDC-ASGPR (49C11) (Li et al., 2012), αDCIR
(9E8) (Klechevsky et al., 2010), αCD40 (12E12) (Flamar et al., 2013),
αDectin-1 (15E2) (Ni et al., 2010), αDEC205 (MG38) (Bonifaz et al.,
2002), and αLangerin (4C7)] were used. mAbs speciﬁc for the
ectodomains of human MARCO (11A8), CLEC6 (9B9), and DC-SIGN/L
(16E7) were generated using receptor ectodomain.hIgG (human IgG1
Fc) and human placental alkaline phosphatase (AP), as previously
described (Ni et al., 2010). Cloned mAbs were puriﬁed by HPLC using
MabSelect resin (GEHealthcare). The speciﬁcities ofmAbswere veriﬁed
by their speciﬁc binding to corresponding receptors expressed on 293F
cells transfected with the full-length receptors. The speciﬁcities of the
mAbswere also conﬁrmed by ELISA by comparing them to the recombi-
nant receptor-Fc and hIgG-Fc fusion proteins (Ni et al., 2010). Chimeric
mAbs containing human IgG4 heavy chain with two site mutations
(S228P and L235E) (Reddy et al., 2000) were made to further abolish
non-speciﬁc binding to Fc receptors.
2.3. mAb-Doc, Coh-antigen and Their Conjugates
Recombinant fusionproteins ofmAb-dockerin (Doc), cohesin (Coh)-
Flu.M158–66, and Coh-MART-126–35 (27L) were previously described
(Flamar et al., 2012; Ni et al., 2010). mAb-antigen conjugates were
formed by mixing one molar equivalent of mAb-Doc with two molar
equivalents of Coh-antigen proteins in 1X PBS with Ca2+ and Mg2+
(Biosources). The Doc and Coh domains self-associate, forming a stable
and speciﬁc complex.
2.4. Recombinant Fusion Proteins of mAb-Flu.NP, -Flu.HA1 and -HPV16.E6/7
Production of mAb-NP and mAb-HA1 proteins was as previously
described (Li et al., 2012; Skinner et al., 2014). Fusion proteins bearing
the E6 and E7 proteins of HPV16 were made using the same method.
2.5. Cells
All healthy (cancer-free) blood donors provided a written informed
consent prior to inclusion in the study in accordance with the approval
by the Institutional Review Boards at Baylor Research Institute. Mo-DCs
were prepared by culturing puriﬁed blood monocytes from healthy
individuals. Brieﬂy, monocytes enriched from fresh peripheral blood
mononuclear cells (PBMCs) or frozen elutriated cell fractions were cul-
tured in DC culture medium (CellGenix) in the presence of 100 ng/ml
human GM-CSF and 50 ng/ml IL-4 for 6 days. On day 3, culturemedium
was replaced with fresh medium containing the same concentrations
of GM-CSF and IL-4. PBMCs of HLA-A*0201+ healthy donors were
fractionated by elutriation. Total CD4+ and CD8+ T cells were enriched
using enrichment kits (StemCell Technologies). Naïve CD8+ T cells
(CD45RA+CD45RO−) (purity N99.2%)were further sorted on a FACSAria
II (BD Biosciences). Monocytes and total B cells were puriﬁed using
enrichment kits (StemCell Technologies). Blood myeloid DCs (mDCs,
Lin-1−HLA-DR+CD11c+CD123−) and plasmacytoid DCs (pDCs,
Lin-1−HLA-DR+CD11c−CD123+) were pre-enriched using a pan-
DC enrichment kit (StemCell Technologies) and then sorted. All ﬂow
cytometry data were collected on a FACSCanto II (BD Biosciences) and
analyzed with FlowJo v9 (Tree Star).
2.6. T Cell Assays
A total of 5 × 103 monocyte-derived DCs (Mo-DCs) were loaded
with the indicated amounts of recombinant proteins or antigens and
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for nine days in the presence of 20 units/mL IL-2 and 10units/mL IL-7. In
experiments using PBMCs, 50 units/mL IL-15 was added to the cultures
on day 2. RPMI 1640 medium (Gibco), supplemented with 10% heat-
inactivated human AB serum (Gemini), 50 unit/mL penicillin,
50 μg/mL streptomycin, 2 mM L-glutamate, non-essential amino acids
(Sigma), 25mMHEPES (Life Technologies), and 1mM sodiumpyruvate
(Sigma), was used. CD8+ T cells were then stained with tetramer
and αCD8 mAb. In some experiments, CD8+ T cells were stained
with tetramer, αGranzyme B and αPerforin mAbs at the same time.
To assess intracellular IFNγ expression, T cells were restimulated
with the indicated peptides for 6 h in the presence of brefeldin A (BD
Biosciences), as per the manufacturer's protocols. To measure cytotox-
icity of CD8+ T cells, a 5 h 51Cr-release assay was performed using
T2 cells loaded with the indicated peptides. The cytotoxicity of
MART-126–35-speciﬁc CD8+ T cells was also measured using cell lines
(MEL290 and K562) that were grown in complete RPMI 1640 medium
containing 10% FCS (Gemini).
2.7. Immunoﬂuorescence
Mo-DCs (2 × 105/well) were plated in 24-well culture plates.αCD40
(12E12), αLOX-1 (15C4), or αDectin-1 (15E2) mAbs conjugated with
Alexa Fluor 647 were added at 1 μg/mL followed by a 1-h incubation
on ice. For internalization assays, cells were incubated for 1 h in a CO2
incubator at 37 °C. Cells were preﬁxed with 3% paraformaldehyde
(Polysciences) for 30 min on ice and then ﬁxed for 20 min at room
temperature. Cells were then stained with Alexa Fluor 488-coupled
rabbit anti-human early endosome antigen 1 (EEA1) or anti-human
lysosomal-associated membrane protein 1 (LAMP-1) in PBS containing
0.1% saponin. Each optical slice was 0.5 μm thick. Images were acquired
on a Leica DMI16000 confocal microscope (Nanterre, France). Image-J
software was used to perform image analysis, channel imaging, and
surface plotting (3D presentation). For each donor (n = 9) and each
labeling antibody (αCD40, αLOX-1, and αDectin-1 mAbs), at least 10
pictures each with more than 10 cells were taken and analyzed. Just
another Colocalization Plugin (JaCoP) software was used to calculate
Mander's coefﬁcients.
2.8. Animals and Immunization
All mouse experiments were conducted with the approval of the
Institutional Animal Care and Use Committee at Baylor Research
Institute. Animals were housed in a pathogen-free environment at
the animal facility of Baylor Research Institute. All facilities received
daily monitoring and care from the animal facility staff under the
supervision of a veterinarian. A maximum of 5 mice were housed
per cage. hCD40Tg mice (ImmuRx) and wild-type C57BL/6 (Jackson
Laboratory) used were 6-to-10-week-old females. Animals were
immunized either s.c. or i.p., as indicated, on days 0, 14 and 28,
with 100 μL PBS containing 30 μg of either αCD40-HPV16.E6/7 or
αLangerin-HPV16.E6/7 and 50 μg polyinosinic:polycytidylic acid
[poly(I:C)] (Invivogen). Anesthesia and euthanasia was achieved by
cervical dislocation after the mice were made unconscious from
exposure to isoﬂurane. During anesthesia, peripheral blood was
collected from the retro-orbital sinus and used for tetramer staining.
Spleens were collected after euthanasia and processed into single-cell
suspension for ELISpot assays.
2.9. ELISpot Assays
Mouse IFNγ ELISpotPlus pre-coated plates and reagents were obtain-
ed from Mabtech. Brieﬂy, puriﬁed splenic CD4+ and CD8+ T cells
from immunized mice were stimulated with γ-irradiated wild-type
splenocytes loaded with the indicated peptide pools (1 μM). After a
40 h incubation, plates were washed and incubated with biotinylatedrat anti-mouse IFNγ for 2 h. After washing the plates, streptavidin-
horseradish peroxidase (HRP) was added and incubated for 1 h. IFNγ
was detected using 3,3′,5,5′-tetramethylbenzidine (TMB). The reaction
was terminated once the formation of discrete purple-colored spots
was detected. Spots were counted using ELISpot services (Zellnet
Consulting).
2.10. Statistics
Statistical signiﬁcance was determined using the analysis of
variance (ANOVA) and Student's t-test with Prism 6 software
(GraphPad Software). Signiﬁcance was set at P b 0.05.
2.11. Accession Codes
GenBank references for mAbs and recombinant proteins are
αMARCO (11A8): KP684033 and KP684034; αDC-SIGN (16E7):
HQ912690.1 and HQ912691.1; αCLEC6 (9B9): KP684031 and
KP684032; αLangerin (4C7): JX002669.
3. Results
3.1. The Superiority of CD40 Over Eight Other Receptors for CD8+ T Cell
Cross-priming
Herein, we compared the levels of MART-126–35-speciﬁc
CD8+ T cell responses primed with Mo-DCs loaded with different
mAb-MART-126–35 (27L) conjugates. We used nine mAbs that were
speciﬁc to different DC surface receptors. All mAbs were engineered as
chimeras containing the mouse V-region and human IgG4 Fc with two
mutations (S228P and L235E) to further abolish their non-speciﬁc
binding to Fc receptors (Reddy et al., 2000). mAb-antigen conjugates
were made through non-covalent stable interactions between Coh-
antigen and mAb-Doc, and they were well suited for targeting antigens
to DCs via surface receptors (Flamar et al., 2013; Ni et al., 2010).Mo-DCs
generated in serum-free DC culture medium containing GM-CSF and
IL-4 expressed CD11c, CD14, costimulatory molecules (CD80, CD83,
CD86) and high levels of HLA-ABC and HLA-DR (Supplemental
Fig. 1A). However, the expression levels of such surface molecules
were variable amongMo-DCs generatedwithmonocytes from different
donors (Supplemental Fig. 1B).
Fig. 1A shows that DCs loaded with any of the eight different
mAb-MART-126–35 (27L) conjugates were able to prime various levels
ofMART-126–35-speciﬁc CD8+T cell responses, asmeasured by tetramer
staining. DCs loaded with conjugates made with αLOX-1 and αDEC205
resulted in similar levels of MART-126–35-speciﬁc CD8+ T cell responses,
but they were more efﬁcient at priming MART-126–35-speciﬁc CD8+
CTLs than conjugates made with other mAbs (αDC-ASGPR, αCLEC6,
αMARCO, and control IgG4). Thus, we selected the αLOX-1 conjugate
and compared it to αCD40 and αDectin-1 conjugates in the second
experiments (Fig. 1B). The αCD40 conjugate was more efﬁcient than
the other two at priming MART-126–35-speciﬁc naïve CD8+ T cells.
Representative tetramer staining data for Fig. 1A and B are presented
in Supplemental Fig. 2A andB, respectively.
Fig. 1C shows that DCs expressed higher levels of CD40 and DCIR
than other receptors tested, although the αDCIR conjugate was less ef-
ﬁcient than the αLOX-1 conjugate at priming MART-126–35-speciﬁc
naïve CD8+ T cells. DCs also expressed slightly higher levels of DC-
SIGN/L, DEC205, and DC-ASGPR than LOX-1, CLEC6, and Dectin-1.
These data suggested that the magnitude of antigen-speciﬁc CD8+ T
cell responses elicited with different mAb-MART-126–35 (27L) conjugates
(Fig. 1A and B) does not necessarily correlate with the surface
expression levels of the receptors targeted or consequentlywith antigen
loads (Reuter et al., 2015). We thus concluded that the αCD40-
MART-126–35 (27L) conjugate was more efﬁcient than eight other
mAb conjugates at priming MART-126–35-speciﬁc CD8+ T cells.
Fig. 1. The superiority of CD40 over eight other receptors for CD8+ T cell cross-priming. A and B. Puriﬁed naïve CD8+ T cells were co-cultured with Mo-DCs loaded with 1 μg/mL
mAb-MART-126–35(27L) for 9 days. CD8+ T cells were then stained with HLA-A*A0201-MART-126–35 tetramer. Dots represent data generated with cells from individual healthy donors
(n = 9). Data are presented as mean ± SD, and signiﬁcance was determined using an ANOVA test. C. Mo-DCs were stained with 1 μg/mL of the indicated ﬂuorescence-labeled mAbs
and analyzed by ﬂow cytometry. Representative ﬂow cytometric data out of three experiments are shown. *, P b 0.05; **, P b 0.01; ***, P b 0.005; ****, P b 0.001; ns, not signiﬁcant.
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Next, we tested whether αCD40-MART-126–35 (27L) conjugate could
target CD40 expressed on DCs. DCswere loadedwith two different con-
centrations ofαCD40-MART-126–35 (27L) conjugate and then co-cultured
for nine days with autologous naïve CD8+ T cells. As shown in Fig. 2A,
DCs loaded with αCD40 conjugate primed MART-126–35-speciﬁc CD8+
T cells at both 5 and 1 μg/mL; whereas DCs loaded with 5 μg/mL IgG4
conjugate only resulted in a minimal level of CD8+ T cell priming.
Summarized data from 13 independent experiments using cells from
different healthy donors are presented (Fig. 2A, right panel). In addition,
DCs loaded with 5 nM (1 μg/mL) αCD40-MART-126–35 (27L) conjugate,
which contains 10 nM MART-126–35 (27L), were far more efﬁcient than
DCs loaded with 10 nM MART-126–35 (27L) peptide (Fig. 2B). Targeting
MART-126–35 (27L) toDCs via CD40was at least 1000 timesmore efﬁcient
at priming MART-126–35-speciﬁc CD8+ T cells than the non-targeted
loading of MART-126–35 (27L) onto DCs (Fig. 2B). Summarized data
generated with cells from six different donors are presented (Fig. 2B,
right panel).
Fractions of MART-126–35-speciﬁc CD8+ T cells primed with DCs
loaded with αCD40-MART-126–35 (27L) conjugate expressed both
granzyme B and perforin (Fig. 2C). They were also able to lyse T2 cells
loaded with 10 μM MART-126–35. CD8+ CTLs that were primed with
IgG4-MART-126–35 (27L) conjugate-loaded DCs showed minimal killing
activity (Fig. 2D). As shown in Fig. 2E, MART-126–35-speciﬁc CD8+ CTLs
that were primed withαCD40-MART-126–35 (27L) conjugate-loaded DCs
could also lyse MEL290 cells (HLA-A*0201+ and MART-1+) but not the
control cell line K562 (Fig. 2E, left panel). CD8+ T cells primed with
IgG4-MART-126–35 (27L) conjugate-loaded DCs could not speciﬁcally
lyse MEL290 (Fig. 2E, right panel).
The functional activities of CD8+ CTLs primed with αCD40-
MART-126–35 (27L) conjugate-loaded DCs were further comparedwith those primed with four other mAb-MART-126–35 (27L) conju-
gates. DCs loaded with αCD40-MART-126–35 (27L) conjugate induced
a greater frequency of IFNγ+ and TNFα+CD8+ T cell responses
than the other four (Supplemental Fig. 3A). This was further support-
ed by the data in Supplemental Fig. 3B, showing that CD8+ CTLs
primed with αCD40-MART-126–35 (27L) conjugate-loaded DCs were
more efﬁcient than those primed with other mAb-MART-126–35
(27L) conjugate-loaded DCs at lysing T2 cells. We therefore concluded
that αCD40-MART-126–35 (27L) conjugate targeted CD40 and could
thus efﬁciently prime functional MART-126–35-speciﬁc CD8+ CTLs.
3.3. The Superiority of CD40 Over LOX-1 and Dectin-1 for BoostingMemory
CD8+ CTLs
We compared the levels of Flu.M158–66-speciﬁc memory CD8+ T
cell responses elicited by DCs loaded with αCD40 conjugates
with those elicited by αDectin-1 and αLOX-1 conjugates. These
mAbs (αDectin-1 and αLOX-1) were selected based on the data in
Fig. 1A and B. Fig. 3A shows that DCs loaded with 0.1 μg/mL
αCD40-Flu.M158–66 conjugate were more efﬁcient than DCs loaded
with the same concentration of αLOX-1- or αDectin-1-Flu.M158–66
conjugate at activating Flu.M158–66-speciﬁc CD8+ T cells, as mea-
sured by tetramer staining. Similarly, when compared with six
other mAb-Flu.M158–66 conjugates, DCs loaded with αCD40-Flu.M158–66
conjugate resulted in the greatest level of Flu.M158–66-speciﬁc CD8+ T
cell activation (Supplemental Fig. 4A and B). Fig. 3B (left panel) further
demonstrates that DCs loaded with αCD40-Flu.M158–66 conjugate are
far more efﬁcient than DCs loaded with the equimolar amounts of
Flu.M158–66. Data from ﬁve independent experiments using cells from
different healthy donors (n = 6) are shown in Fig. 3B (right panel).
Fractions of Flu.M158–66-speciﬁc CD8+ CTLs elicited by DCs loaded
with αCD40-Flu.M158–66 conjugate expressed granzyme B and perforin
Fig. 2. CD8+ CTLs primed with CD40-targeted DCs are functional. A. Puriﬁed naïve CD8 T cells were co-cultured with Mo-DCs loadedwith the indicated amounts ofαCD40-MART-126–35
(27L) or IgG4-MART-126–35 (27L) conjugates for 9 days. CD8+ T cells were then stained with HLA-A*A0201-MART-126–35 tetramer. Representative ﬂow cytometric data (left) and donor-
matched frequencies of MART-126–35-speciﬁc CD8+ T cells induced with αCD40-MART-126–35 (27L)- or IgG4-MART-126–35 (27L)-loaded Mo-DCs are shown (right). Dots represent data
generated with cells from individual healthy donors (n = 13). Signiﬁcance was determined using a paired t-test. B. As in A, puriﬁed naïve CD8+ T cells were co-cultured with Mo-DCs
loaded with the indicated amounts of αCD40-MART-126–35 (27L) conjugate or MART-126–35 (27L) peptide. CD8+ T cells were stained with HLA-A*A0201-MART-126–35 tetramer. Represen-
tative ﬂow cytometric data (left) and summarized data (right). Dots represent data generated with cells from individual healthy donors (n= 6). Data are presented as mean ± SD. Sig-
niﬁcance was determined using an ANOVA test. C. CD8+ T cells in A primedwithMo-DCs loaded with 1 μg/mLmAb-MART-126–35 (27L) were stained for granzyme B and perforin.D. A 5 h
51Cr release assay using T2 cells loaded with 10 μMMART-126–35 peptide were used as target cells. CD8+ T cells primed with Mo-DCs loaded with 1 μg/mL αCD40-MART-126–35 (27L) or
IgG4-MART-126–35 (27L) were used as effector cells. E. A 5 h 51Cr release assay using MEL290 and control K562 cell lines as target cells. CD8+ T cells primed with Mo-DCs loaded with
1 μg/mL αCD40-MART-126–35 (27L) (left) or IgG4-MART-126–35 (27L) (right) were used as effector cells. Error bars in D and E indicate SD of triplicate assays. Signiﬁcance was determined
using an ANOVA test. Two independent experiments resulted in similar data. *, P b 0.05; **, P b 0.01; ***, P b 0.005; ****, P b 0.001; ns, not signiﬁcant.
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able to lyse T2 cells loaded with Flu.M158–66 peptide at both 10
and 1 nM (Fig. 3E, left panel), while CD8+ CTLs elicited with IgG4-
Flu.M158–66 conjugate only lysed target cells loaded with 10 nM
Flu.M158–66 peptide (Fig. 3E, right panel). Taken together, we concludedthat αCD40-Flu.M158–66 conjugate targeted CD40 and could thus efﬁ-
ciently activate Flu.M158–66-speciﬁc memory CD8+ CTLs. In addition,
targeting Flu.M158–66 to DCs via CD40 is more efﬁcient at boosting
Flu.M158–66-speciﬁc CD8+ T cell responses than targeting Flu.M158–66
to other receptors (Supplemental Fig. 4), including LOX-1 or Dectin-1.
Fig. 3. The superiority of CD40 over LOX-1 and Dectin-1 for boosting functional memory CD8+ CTLs. A–C. Puriﬁed CD8+ T cells were co-cultured with Mo-DCs loaded with
the indicated amounts of mAb-Flu.M158–66 conjugates or Flu.M158–66 peptide. CD8+ T cells were then stained with HLA-A*A0201-Flu.M158–66 tetramer. A. Frequencies of
Flu.M158–66-speciﬁc CD8+ T cells activated by Mo-DCs loaded with 0.1 μg/mL mAb-Flu.M158–66 conjugates. Dots represent data generated with cells from healthy donors
(n = 5). B. Frequencies of Flu.M158–66-speciﬁc CD8+ T cells elicited by Mo-DCs loaded with αCD40-Flu.M158–66 at 10, 1, 0.1 nM, or with Flu.M158–66 peptide at 20, 2, 0.2 nM.
Each Flu.M158–66 conjugate molecule contains two molecules of Flu.M158–66 antigen. Representative ﬂow cytometric data (left) and summarized data (mean ± SD) from ﬁve
independent experiments (n = 6) are presented. C. CD8+ T cells activated with Mo-DCs loaded with αCD40-Flu.M158–66 or IgG4-Flu.M158–66 in A were further stained for granzyme B
and perforin. Three independent experiments showed similar results. Representative ﬂow cytometric data on the frequencies of Flu.M158–66-speciﬁc granzyme B+ or perforin+CD8+
T cells are shown. D. CD8+ T cells activated with Mo-DCs loaded with αCD40-Flu.M158–66 or IgG4-Flu.M158–66 in A were restimulated with 1 μM Flu.M1 peptide, and intracellular IFNγ
expression was assessed. Three independent experiments showed similar results. Representative ﬂow cytometric data on the frequencies of Flu.M158–66-speciﬁc IFNγ+CD8+ T cells
are shown. E. A 5 h 51Cr release assay using T2 cells loaded with the indicated amounts of Flu.M158–66 peptide. CD8+ T cells activated with Mo-DCs loaded with 0.1 μg/mL
αCD40-Flu.M158–66 or IgG4-Flu.M158–66 were used as effector cells. Error bars indicate SD of triplicate assays. Three independent experiments resulted in similar data. Signiﬁcance in
A, B and E was determined using an ANOVA test. *, P b 0.05; **, P b 0.01; ***, P b 0.005; ****, P b 0.001; ns, not signiﬁcant.
51W. Yin et al. / EBioMedicine 5 (2016) 46–583.4. Distinct Functions of CD40 and Lectins (e.g., LOX-1 and Dectin-1) at
Eliciting T Cell Responses
To further conﬁrm the specialized function of CD40 for enhancing
antigen cross-presentation to CD8+ T cells, we used recombinant fusion
proteins of mAbs and inﬂuenza viral nucleoprotein (Flu.NP). Experi-
ments performed with recombinant fusion proteins of mAbs and
whole protein antigens (e.g., Flu.NP) are thought to be a more biologi-
cally relevant way to assess the ability of DCs to cross-present antigens
and subsequently should be utilized for the rational design of vaccines
against cancers and microbial infections. It also allows us to assess the
multiple repertoires of antigen-speciﬁc CD8+ as well as CD4+ T cell
responses. CFSE-labeled PBMCs were cultured for eight days withαCD40-Flu.NP, αLOX-1-Flu.NP or αDectin-1-Flu.NP fusion proteins.
They were then restimulated with a Flu.NP peptide pool to measure
intracellular IFNγ expression. As shown in Fig. 4A (left panel),
αCD40-Flu.NP fusion protein was more efﬁcient than αLOX-1-
Flu.NP or αDectin-1-Flu.NP fusion protein at activating Flu.NP-
speciﬁc IFNγ+CD8+ T cells. Data from nine independent experiments
using cells from different healthy donors are summarized in Fig. 4A
(right panel). Interestingly, however, αCD40-Flu.NP fusion protein
was signiﬁcantly less efﬁcient than αLOX-1-Flu.NP or αDectin-1-
Flu.NP fusion protein at activating Flu.NP-speciﬁc IFNγ+CD4+ T cells
(Fig. 4, left panel). Data from nine independent experiments further
conﬁrmed this (Fig. 4B, right panel). αLOX-1-Flu.NP and αDectin-1-
Flu.NP fusion proteins resulted in similar levels of Flu.NP-speciﬁc
Fig. 4. Functional specialty of CD40 and lectins (e.g., LOX-1 andDectin-1) in enhancing CD8+ and CD4+T cell responses, respectively.A–C.CFSE-labeled PBMCs fromhealthy donors (n ≥ 6)
were cultured in thepresence of 0.5 μg/mL of the indicated (A andB)mAb-Flu.NP or (C)mAb-Flu.HA1 recombinant fusion proteins for 8 days. Cellswere restimulatedwithNP inA andB or
HA1 peptide pool in C at 1 μM (of each peptide), and intracellular IFNγ expression in live (A) CD8+ and (B and C) CD4+ T cells was assessed. Representative ﬂow cytometric data on the
frequencies of CFSE−IFNγ+ (A) CD8+ or (B and C) CD4+ T cells (left) and donor-matched frequencies of CFSE−IFNγ+ (A) CD8+ and (B and C) CD4+ T cells (bottom) are shown. Dots
represent data generated with cells from individual donors, and signiﬁcance was determined using a paired t-test. *, P b 0.05; ns, not signiﬁcant.
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between CD40 and the other two receptors at eliciting CD4+ T cell re-
sponses was further conﬁrmed by assessing inﬂuenza hemagglutinin
subunit 1 (Flu.HA1)-speciﬁc IFNγ+CD4+ T cell responses elicited with
Flu.HA1 fusion proteins of the three mAbs (Fig. 4C). αCD40-Flu.HA1
fusion protein was less efﬁcient than αLOX-1-Flu.HA1 or αDectin-1-
Flu.HA1 fusion protein at eliciting Flu.HA1-speciﬁc CD4+ T cell re-
sponses. We also measured Flu.HA1-speciﬁc CD8+ T cell responses
(Supplemental Fig. 5), but there was no signiﬁcant level of Flu.HA1-
speciﬁc CD8+ T cell responses to the three mAb-Flu.HA1 fusion pro-
teins. Previous studies (Lee et al., 2008; McMichael et al., 1986;Townsend and Skehel, 1982) have shown that inﬂuenza-speciﬁc
CD8+ memory T cells mostly target internal proteins, including
Flu.NP, but not outer membrane proteins, such as Flu.HA1. Supplemen-
tal Fig. 6A and B demonstrate that the variability of the magnitude of
Flu.NP- and Flu.HA1-speciﬁc T cell responses among donors (as ob-
served in Fig. 4) was mainly due to the variability of the frequencies of
pre-existing Flu.NP- and Flu.HA1-speciﬁc memory T cells of the donors.
PBMCs from nine healthy donors were stimulated with Flu.NP or
Flu.HA1 peptide pools. The frequencies of Flu.NP- and Flu.HA1-speciﬁc
CD4+ and CD8+ T cells were measured by intracellular IFNγ staining.
Taken together, we concluded that CD40 has a specialized function to
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tion to CD4+ T cells, in contrast to LOX-1 and Dectin-1,which promoted
CD4+ but not CD8+ T cells.
Not only DCs, but also monocytes and B cells express CD40 (Flamar
et al., 2013), LOX-1 (Li et al., 2012), and Dectin-1 (Ni et al., 2010).
Therefore, both monocytes and B cells targeted with antigens could
also contribute to the CD4+ and CD8+ T cell responses observed in
Fig. 4. However, we have previously reported that the majority of
antigen-speciﬁc T cell responses elicited by targeting antigens to CD40
and LOX-1 were due to the roles of DCs (Flamar et al., 2013; Li et al.,
2012). Supplemental Fig. 7 further demonstrates that DCs, particularly
mDCs, loaded with αDectin-1-Flu.HA1 fusion protein are far more
efﬁcient than loaded pDCs, monocytes, or B cells at eliciting Flu.HA1-
speciﬁc T cell responses.
3.5. Distinct Patterns of mAb Localization in Subcellular and Intracellular
Compartments
The cellular compartments where antigens are delivered can impact
the outcome of antigen cross-presentation by DCs (Belizaire andFig. 5.Distinct patterns of subcellular and intracellular localization ofαCD40,αLOX-1 andαDec
mAbs at 1 μg/mL. DCs were further stained with αLAMP-1 and αEEA1 antibodies. Images we
images of CD40, LOX-1 or Dectin-1 (red) staining and LAMP-1 or EEA-1 (green) staining ar
plotted based on the ﬂuorescence intensity (z-axis) and merged images in A. Scale bars indic
using the Just Another Colocalization Plugin Software (JaCoP). M1 represents the percentage
represents the percentage of αCD40, αLOX-1, or αDectin-1 that overlaps with αEEA1 or αLA
least 100 cells from 10 pictures were acquired to calculate the colocalization values. Dots repr
ANOVA test. ****, P b 0.001; ns, not signiﬁcant.Unanue, 2009; Burgdorf et al., 2007, 2008; Chatterjee et al., 2012;
Cohn et al., 2013; Harding et al., 1991; Zehner et al., 2011). To further
understand the functional specialties of CD40, LOX-1, and Dectin-1
that have been observed in this study, we examined subcellular and
intracellular localization of receptor-bound αCD40, αLOX-1, and
αDectin-1 mAbs in DCs (Fig. 5). We found two major differences be-
tween αCD40 and the other two mAbs. First, a large fraction of αCD40
mAb stayed at the plasma membrane of DCs (Fig. 5A, left panels). In
contrast, themajority ofαLOX-1 andαDectin-1mAbswere internalized
into the cell cytoplasm within 1 h (Fig. 5A, middle and right panels).
Second,αCD40mAb that did internalize into the cytosolic compartment
mainly accumulated in the early endosomes, as it co-localized with
αEEA1 mAb (Fig. 5A, left panels). In contrast, signiﬁcant fractions of
αLOX-1 (Fig. 5A, middle panels) and αDectin-1 mAbs (Fig. 5A, right
panels) localized into both the early and late endosomes, as they
co-localized with αEEA1 as well as αLAMP-1 mAb that targets the late
endosomes). These observations were further conﬁrmed by the
Mander's coefﬁcients acquired by using the Image-J software (Fig. 5B
and C). M1 represents the fraction of αEEA1 or αLAMP-1 mAb that
overlaps withαCD40,αLOX-1, orαDectin-1 mAb; while M2 representstin-1mAbs.A–C. Mo-DCswere incubatedwith ﬂuorescentαCD40,αLOX-1, andαDectin-1
re acquired on a Leica DMI16000 confocal microscope (100X). A. Representative merged
e shown. Scale bar indicates 10 μm. B. Representative three-dimensional graphs were
ate 10 μm on both x-axis and y-axis. Mander's coefﬁcients, M1 and M2, were calculated
of αEEA1 or αLAMP-1 mAb that overlaps with αCD40, αLOX-1, or αDectin-1 mAb. M2
MP-1 mAb. C. Summarized data represent M1 and M2 from 9 donors. For each donor, at
esent individual donors and error bars indicate SD. Signiﬁcance was determined using an
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αEEA1 or αLAMP-1 mAb. Only ~10% of DCs showed co-localization of
αCD40 and αLAMP-1 mAbs, while more than 75% of DCs showed
co-localization of αCD40 and αEEA-1 mAbs. In contrast to αCD40
mAb, 35–45% of DCs showed co-localization of αLOX-1 and αLAMP-1
mAbs. αDectin-1 mAb showed patterns of subcellular localization that
were similar to what were observed with αLOX-1 mAb. Summarized
data from nine donors, each with analyses done on at least 100 cells,
are shown in Fig. 5C. Taken together, the patterns of subcellular and in-
tracellular localization of CD40-bound αCD40 mAb were distinct from
those of αLOX-1 and αDectin-1 mAbs, which showed a high similarity.
3.6. CD40 Targeting Leads to Greater and Prolonged Antigen
Cross-presentation to CD8+ T Cells
To further understand themechanistic insights for the superiority of
CD40 over other receptors, we investigated the kinetics of antigen pre-
sentation by DCs targeted with different mAb-Flu.M158–66 conjugates.
CFSE-labeled Flu.M158–66-speciﬁc CD8+ T cell lines were co-cultured
with DCs incubated for different time periods (0, 3, 6, 12, and 24 h)
with the three different mAb-Flu.M158–66 conjugates (Fig. 6). CD8+ T
cell proliferation was assessed on day 6 by measuring CFSE dilution.
As shown in Fig. 6A and B, DCs loaded with αCD40-Flu.M158–66
conjugate were more efﬁcient than DCs loaded with the other two
mAb-Flu.M158–66 conjugates at all time points tested. This indicatesFig. 6. Kinetics of antigen cross-presentation of DCs targeted via CD40, LOX-1, or Dectin-1.
A and B. CFSE-labeled Flu.M158–66-speciﬁc CD8+ T cell lines were co-cultured with
Mo-DCs pre-incubated for the indicated time periods with 1 nM (0.1 μg/ml) mAb-
Flu.M158–66 fusion proteins. On day 6, CD8+ T cell proliferation was assessed by ﬂow
cytometry. A. Representative ﬂow cytometric data from 0 and 24 h. B. Summarized
data are presented as mean ± SD of triplicate assays. Signiﬁcance was determined
using an ANOVA test. Two independent experiments resulted in similar data. *, P b 0.05;
***, P b 0.005; ****, P b 0.001.that CD40-targeted antigens can be more efﬁciently cross-presented
in the context ofMHC class I than LOX-1- or Dectin-1-targeted antigens.
It also indicates that DCs targeted with antigens via CD40 are able to
present antigens for a longer time period than DCs targeted with anti-
gens via Dectin-1 or LOX-1. This prolonged antigen cross-presentation
by CD40-targeted DCs was not due to the activation effects of αCD40
in the fusion protein, as assessed by measuring surface phenotypes
of DCs as well as cytokine and chemokine secretion by DCs (data
not shown). This was consistent with previously published data
(Chatterjee et al., 2012). One clear difference between CD40 and lectins
(e.g., LOX-1 and Dectin-1) was in the localization of mAbs (Fig. 5). The
majority of αLOX-1 and αDectin-1 was internalized within 1 h,
but a large fraction of αCD40 remained at the plasma membrane.
Nonetheless, some αCD40 was internalized (mainly to the early
endosomes, which is an important path for antigen cross-presentation
by DCs to CD8+ T cells) (Burgdorf et al., 2007, 2008; Cohn et al.,
2013). In addition, the ability of CD40 tomaintainαCD40 on the plasma
membrane instead of being degraded after internalization could reﬂect
a continuous release of antigens to early endosomes over an extended
period of time for continuous antigen cross-presentation to CD8+ T
cells (Fig. 6). Taken together, we concluded that antigen targeting to
DCs via CD40 results in greater CD8+ T cell responses than targeting
to LOX-1 and Dectin-1. This is due to enhanced antigen cross-
presentation by DCs at early time points as well as for an extended
time period, as shown in Fig. 6.
3.7. CD40 Targeting Evokes Potent CD8+ T Cell Responses in hCD40Tg Mice
Recombinant fusion proteins of αCD40 mAb (clone 12E12) and
HPV16.E6/7 proteins (αCD40-HPV16.E6/7) were generated as de-
scribed before (Flamar et al., 2013; Joo et al., 2014; Li et al., 2012). As
shown in Fig. 7A, αCD40-HPV16.E6/7 bound to splenic CD11c+ DCs
and B220+ B cells but not to CD3+ T cells from the hCD40Tg animals.
αCD40-HPV16.E6/7 did not bind to any of the cell types from wild-
type C57BL/6 mice (data not shown). Consistently, only spleens of
hCD40Tg animals showed HPV16.E6/7-speciﬁc IFNγ+CD8+ (Fig. 7B)
and CD4+ T cell responses (Fig. 7C), as assessed by IFNγ ELISpot assay,
after receiving three doses of αCD40-HPV16.E6/7 (30 μg/dose) plus
poly(I:C) (50 μg/dose) (Bonifaz et al., 2002; Gurer et al., 2008).Without
poly(I:C), αCD40-HPV16.E6/7 could not elicit E6/7-speciﬁc T cell
responses (data not shown).
Using the hCD40Tg animals, wewere also able to compare CD40 and
Langerin, another lectin receptor, for their ability to evoke antigen-
speciﬁc CD8+ and CD4+ T cell responses in vivo. αLangerin mAb
(clone 4C7) binds to both human and murine Langerin (Igyarto et al.,
2011). In addition, αLangerin mAb injected intraperitoneally (i.p.)
effectively targeted Langerin+ cells in mice (Igyarto et al., 2011). We
thus immunized animals with combinations of poly(I:C) (50 μg) plus
either 30 μg αCD40-HPV16.E6/7 or αLangerin-HPV16.E6/7 by i.p.
three times at two-week intervals. Seven days after the secondboosting,
blood E7-speciﬁc CD8+ T cells were assessed by H-2Db-RAHYNIVTF
tetramer staining (Fig. 7D). Compared to animals immunized with
αLangerin-HPV16.E6/7, those immunized with αCD40-HPV16.E6/7
had a higher percentage of tetramer+CD8+ T cells. IFNγ ELISpot assays
using CD8+ and CD4+ T cells puriﬁed from splenocytes also
showed that animals immunized with αCD40-HPV16.E6/7 had
more IFNγ+CD8+ T cells than those immunized with αLangerin-
HPV16.E6/7 (Fig. 7E, left panel). However, αLangerin-HPV16.E6/7
was signiﬁcantly more efﬁcient than αCD40-HPV16.E6/7 at eliciting
IFNγ+CD4+ T cell responses (Fig. 7E, right panel). It is also of
note that animals immunized with αCD40-HPV16.E6/7 had more
(N2-fold on average) CD8+ than CD4+ T cells that are speciﬁc for
HPV16.E6/7, while those immunized with αLangerin-HPV16.E6/7
had more (N5-fold on average) CD4+ than CD8+ T cells. We
also assessed HPV16.E6/7-speciﬁc T cell responses elicited after
immunizing animals s.c. with the two recombinant fusion proteins.
Fig. 7. Antigen targeting to CD40 can efﬁciently elicit antigen-speciﬁc CD8+ T cell responses in hCD40Tg mice. A. Binding ofαCD40-HPV16.E6/7 (1 μg/mL) to splenic CD11c+ DCs, B220+
B cells, and CD3+ T cells of hCD40Tgmouse.B and C.hCD40Tg orWT animals (n=4per group)were immunized s.c. with a combination ofαCD40-HPV16.E6/7 (30 μg/dose) andpoly(I:C)
(50 μg/dose) in 100 μL PBS. Animals were boosted twice with the same vaccine at two-week intervals and were sacriﬁced 7 days after the second boost. IFNγ ELISpot assays
were performed on (B) CD8+ and (C) CD4+ T cells puriﬁed from splenocytes with HPV16.E6/7 peptide pool at 1 μM as stimulus. D and E. hCD40Tg animals were immunized i.p. with
a combination of poly(I:C) (50 μg/dose) and αCD40-HPV16.E6/7 (30 μg/dose) or αLangerin-HPV16.E6/7 (30 μg/dose) in 100 μL PBS (n = 4 per group). Animals were boosted
twice with the same vaccine at two-week intervals and were sacriﬁced 7 days after the second boost. D. CD8+ T cells in peripheral blood were stained with H-2Db-HPV16.E7RAHYNIVTF
tetramer. Left, representative ﬂow cytometry data. Right, summarized data. E. IFNγ ELISpot assays were performed on CD8+ (left) and CD4+ (right) T cells puriﬁed
from splenocytes. Dots represent data generated with individual animals. All data are presented as mean ± SD. Signiﬁcance was determined using a t-test in (B–D) or ANOVA test
in (E). *, P b 0.05; ****, P b 0.001; ns, not signiﬁcant.
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cantly more effective than αLangerin-HPV16.E6/7 at eliciting
HPV16.E7-speciﬁc CD8+ T cell responses, as measured by staining
CD8+ T cells in the blood with tetramer. ELISpot data generated
with puriﬁed CD8+ and CD4+ T cells from splenocytes also showed
that αCD40-HPV16.E6/7 was more efﬁcient than αLangerin-
HPV16.E6/7 at eliciting E6/7-speciﬁc IFNγ+CD8+ T cell responses
(Supplemental Fig. 8B, left panel), while αLangerin-HPV16.E6/7
was more efﬁcient than αCD40-HPV16.E6/7 at eliciting IFNγ+CD4+
T cell responses (Supplemental Fig. 8B, right panel). A previous study
(Idoyaga et al., 2011) demonstrated that antigen targeting to
Langerin or DEC205 resulted in comparable levels of antigen-
speciﬁc IFNγ+CD8+ T cell responses in mice. Our human in vitro
data (Figs. 1 and 2) demonstrate that CD40 targeting is signiﬁcantlymore efﬁcient than LOX-1, Dectin-1 or DEC205 targeting that
showed similar levels of CD8+ T cell responses. Taking all of these
ﬁndings together, we concluded that targeting antigen to CD40 is
an efﬁcient strategy to evoke antigen-speciﬁc CD8+ T cell responses.
4. Discussion
Understanding the biology of human DC surface receptors and
the functional consequences of the actions of individual receptors
is fundamental for the rational design of medicines for cancers,
inﬂammatory diseases (including autoimmune diseases) and micro-
bial infections. Of the many different receptors expressed on the
surface of DCs, lectin-like receptors are considered to be one of
the major pattern-recognition receptor families. Some of these
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Landmann et al., 2007), DCIR (Fujikado et al., 2008), DC-SIGN
(Geijtenbeek and Gringhuis, 2009), LOX-1 (Joo et al., 2014), and
DC-ASGPR (Li et al., 2012), are known to play important roles
in shaping the quality and quantity of host immune responses.
However, the ability of these receptors to capture antigens and deliv-
er them to intracellular compartments makes them novel targets for
DC antigen delivery to enhance antigen cross-presentation to T cells.
Nonetheless, one major question still remains: “Which targeted
receptor results in optimal antigen cross-presentation to T cells?”
This study has demonstrated that CD40 is superior to nine other
lectins and scavenger receptors at cross-presenting antigen to
CD8+ T cells. This was conﬁrmed with both a tumor-associated self
antigen and different forms of viral antigens. Interestingly, however,
DC lectins (e.g., LOX-1 Dectin-1 and Langerin) were superior to
CD40 at presenting antigens to CD4+ T cells.
To further understand such functional specialization of CD40,we ex-
amined the subcellular and intracellular localization of receptor-bound
mAbs in DCs. Previous studies (Burgdorf et al., 2007, 2008) showed
that early endosomes are essential for the cross-presentation of anti-
gens. Recently, Cohn (Cohn et al., 2013) and Chatterjee (Chatterjee
et al., 2012) also showed that antigen delivery to early endosomes
could result in enhanced antigen cross-presentation to CD8+ T cells,
although antigens in late endosomes and lysosomes can also be cross-
presented. However, these late compartments are far less efﬁcient for
cross-presentation of some antigens. This was due to a higher concen-
tration of lysosomal enzymes, which degrade antigens before they can
be released into the cytosol. In line with this, inhibiting proteolysis en-
hances the ability of the late compartments to cross-present accumulat-
ed antigens (Chatterjee et al., 2012). In this study, we found that
signiﬁcant fractions of receptor-bound αLOX-1 and αDectin-1 mAbs
also localized to the early endosomes, although targeting CD40 was far
more efﬁcient at eliciting CD8+ T cell responses than targeting LOX-1
or Dectin-1. Quantitative analysis of the intracellular compartments
across nine different donors further revealed thatαCD40mAb localized
mainly to the early endosomes, but αLOX-1 and αDectin-1 localized to
both the early and late endosomes. This suggested that there could be
other critical factors in addition to the roles of early endosomes that
can further inﬂuence the efﬁciency of antigen cross-presentation by
DCs via MHC class I molecules. Accordingly, we showed that a large
fraction of αCD40 mAb remained at the plasma membrane even after
a 1-h incubation at 37 °C, whereas the majority of both αLOX-1 and
αDectin-1 mAbs were internalized into endosomal vesicles. Slow inter-
nalization to early endosomes or rapid antigen recycling, as speculated
previously (Chatterjee et al., 2012; Cohn et al., 2013), could result in in-
creased antigen stability, followed by prolonged antigen presentation
and enhanced CD8+ T cell responses, as we have demonstrated in Fig. 6.
In addition to such distinct properties of antibody-bound CD40
versus the lectins (LOX-1 and Dectin-1) described above, one may also
consider the possible contribution of αCD40-mediated activation
signals in the enhanced antigen cross-presentation after targeting
CD40. Previous studies in mice (Bennett et al., 1998; Ridge et al., 1998;
Schoenberger et al., 1998) showed that interactions between APCs
(including DCs) and helper T cells via CD40–CD40L has been suggested
to activate APCs to become fully competent for CD8+ T cell priming. Re-
cent studies have also shown that other DC activators, including toll-like
receptor (TLR) ligands and type 1 IFN, can also promote antigen cross-
presentation (Datta et al., 2003; Maurer et al., 2002; Schulz et al.,
2005;Watts et al., 2007;Wei et al., 2010). However, recombinant fusion
proteins of αCD40 and antigens used in this study were not able to
induceDCs to secrete cytokines or chemokines or induce surface pheno-
type maturation. This was in line with the previous observation
(Chatterjee et al., 2012) that the enhanced antigen cross-presentation
by CD40-targeted human DCs was not due to the CD40-mediated
activation signals. Nonetheless, questions regarding the possible contri-
bution of CD40 signaling in enhanced antigen cross-presentation mayneed to bemore carefully studied in the future. Apart from the question
on mechanistic insights, we may also need to consider the possible
effects of αCD40 bound to CD40 on CD40–CD40L interaction in vivo,
although this may not be a critical issue if a proper DC activator is
included as an adjuvant in the CD40 targeting vaccines, as most likely
it would be (Fig. 7).
In vivo data generated using hCD40Tg animals further demonstrate
that antigen targeting to CD40 is an efﬁcient way to evoke antigen-
speciﬁc CD8+ T cell responses in vivo. Although we could not compare
CD40 with LOX-1 or Dectin-1 in this animal model due to the limited
speciﬁcities of mAbs (αLOX-1 and αDectin-1) to human receptors, we
were able to verify that CD40 targeting was signiﬁcantly more efﬁcient
than Langerin (another lectin receptor) targeting for the elicitation of
antigen-speciﬁc CD8+ T cell responses in vivo. In addition, our in vivo
data further demonstrate that targeting CD40 results in greater CD8+
than CD4+ T cell responses, while Langerin targeting results in greater
CD4+ than CD8+ T cell responses. A previous study (Chatterjee et al.,
2012) has already demonstrated that antigen targeting to three differ-
ent lectin receptors, Langerin, DEC205, andClec9A, resulted in compara-
ble levels of antigen-speciﬁc IFNγ+CD8+ T cell responses in mice. Data
(Figs. 1 and 2) from this study illustrated that targeting LOX-1, Dectin-1
or DEC205 resulted in comparable levels of antigen-speciﬁc CD8+ T cell
responses, but they were less efﬁcient than targeting CD40. Taking all
of these data together, CD40 targeting is more efﬁcient than targeting
the lectin receptors tested in this study. Consistent with both LOX-1
and Dectin-1, antigen targeting to Langerin, a c-type lectin receptor
expressed on Langerhans cells as well as fractions of dermal DCs
(Bonifaz et al., 2004; Delamarre et al., 2003) and CD8α+ DCs
(Delneste, 2004) in mice, resulted in greater levels of antigen-speciﬁc
CD4+ T cell responses.
In summary, this study reports specialized functions of CD40 ver-
sus lectins (e.g., Dectin-1, LOX-1 and Langerin) expressed on the sur-
face of DCs. Data from this study also provide fundamental
information for the rational design of vaccines against cancers and
viral infections. In spite of recent success with the inhibitors of im-
mune checkpoints (e.g., αCTLA4, αPD-1, and αPD-L1 antibodies),
particularly in cancer immunotherapy, there is still a need for
boosting tumor-speciﬁc immunity for better treatment outcomes.
CD40 targeting vaccines could thus be combined with such check-
point inhibitors to provide cancer patients with better clinical bene-
ﬁt that need to be tested in the near future.Author Contributions
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